Device Trial Radar · NCT03010319
PriMatrix for the Management of Diabetic Foot Ulcers
Last checked: Nov 19, 2026Latest source record: Apr 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
226
Actual
Start
Jan 2017
Primary completion
Aug 2020
Study completion Aug 2020
Sponsor
- Lead sponsor
- Integra LifeSciences CorporationPublic (IART)
- Sponsor type
- Industry
- First posted
- Jan 5, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy of PriMatrix Dermal Repair Scaffold in the management of diabetic foot ulcers in subjects with diabetes mellitus versus the Standard of Care treatment. Half of patients will be treated using PriMatrix while the other half will receive Standard of Care treatment.
Conditions
- Diabetic Foot Ulcer
Interventions
PriMatrix Dermal Repair ScaffoldDevice
Application of PriMatrix to ulcer
Secondary DressingsDevice
Dressings to ensure moist wound environment
Offloading deviceDevice
Offloading device to decrease pressure to wound area
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Complete Wound Closure, as Assessed by the Investigator, at or Before Week 12 of the Treatment PhaseTime frame: 12-week Treatment Phase
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
ILD Research Center
Carlsbad, California
LA Foot & Ankle Clinic
Los Angeles, California
Center for Clinical Research, Inc.
San Francisco, California
14 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.